Very Elevated High-Density Lipoprotein Cholesterol and Mortality-The Good Gone Bad?

Sadiya S. Khan; Gregg C. Fonarow

doi:10.1001/jamacardio.2022.0924

Very Elevated High-Density Lipoprotein Cholesterol and Mortality-The Good Gone Bad?

Sadiya S. Khan^*, Gregg C. Fonarow

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Comment/debate › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	681
Number of pages	1
Journal	JAMA cardiology
Volume	7
Issue number	7
DOIs	https://doi.org/10.1001/jamacardio.2022.0924
State	Published - Jul 2022

Funding

receiving grants from the American Heart Association and the National Institutes of Health outside the submitted work. Dr Fonarow reported receiving personal fees from Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Edwards, Janssen, Medtronic, Merck, and Novartis outside the submitted work. No other disclosures were reported.

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1001/jamacardio.2022.0924

Cite this

@article{255b0401e6704195a8107035b7eccf8e,

title = "Very Elevated High-Density Lipoprotein Cholesterol and Mortality-The Good Gone Bad?",

author = "Khan, {Sadiya S.} and Fonarow, {Gregg C.}",

note = "Funding Information: receiving grants from the American Heart Association and the National Institutes of Health outside the submitted work. Dr Fonarow reported receiving personal fees from Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Edwards, Janssen, Medtronic, Merck, and Novartis outside the submitted work. No other disclosures were reported.",

year = "2022",

month = jul,

doi = "10.1001/jamacardio.2022.0924",

language = "English (US)",

volume = "7",

pages = "681",

journal = "JAMA cardiology",

issn = "2380-6583",